An international team of UK and US scientists has discovered that the activity of macrophages—a type of white blood cell that ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

An international team of UK and US scientists discovered that the activity of macrophages -- a type of white blood cell that engulf pathogens and cancer cells -- can be used to predict whether or not ...

PD-L1 is overexpressed by dendritic cells in patients with metastatic castration-resistant prostate cancer ... Five responding tumors were PD-L1–positive and two exhibited DNA damage repair defects.

the most important of which is a PD-L1 test, which helps direct the use of immunotherapy, but also more complicated testing looking for gene mutations in the tumor. "There are two main types of lung ...

Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC ... or metastatic PD-L1-high (50% or greater) NSCLC that ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma ... PD-L1-high patients without mutations ...

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will ...

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on ...

I-Mab, a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment ...

Cemiplimab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Colorectal Cancer.